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BenzimidazoleThe enoyl acyl-carrier protein reductase (ENR) enzyme of the apicomplexan parasite family has been
intensely studied for antiparasitic drug design for over a decade, with the most potent inhibitors target-
ing the NAD+ bound form of the enzyme. However, the higher afﬁnity for the NADH co-factor over NAD+
and its availability in the natural environment makes the NADH complex form of ENR an attractive target.
Herein, we have examined a benzimidazole family of inhibitors which target the NADH form of Francisella
ENR, but despite good efﬁcacy against Toxoplasma gondii, the IC50 for T. gondii ENR is poor, with no inhib-
itory activity at 1 lM. Moreover similar benzimidazole scaffolds are potent against fungi which lack the
ENR enzyme and as such we believe that there may be signiﬁcant off target effects for this family of
inhibitors.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Fatty acid biosynthesis (FAS) is essential for cellular mainte-
nance and survival making it an attractive target for drug design.
Importantly, there are distinct differences between the eukaryotic
and prokaryotic FAS pathways.1 The Eukaryotic system, termed
FAS I, uses one large polypeptide complex, but Prokaryotes use a
series of discrete monofunctional enzymes termed the FAS II path-
way to achieve the same goal.2 Enoyl acyl-carrier protein reductase
(ENR), which carries out the ﬁnal stage of FAS II synthesis, has been
the main focus of drug development programs in this area. This has
resulted in a range of potent ENR inhibitors being developed such
as isoniazid, the diazaborine family and the common antibacterial
triclosan.3–6 The potency and easy synthesis of triclosan has re-
sulted in it being found in a range of common household items
such as toothpastes, mouthwashes and chopping boards. Commonto all of these potent ENR inhibitors is that they bind to the NAD+
complexed form of ENR, despite the NADH co-factor having a high-
er afﬁnity than NAD+ for ENR and likely being equivalently preva-
lent in nature.7 Moreover, the NADH/NAD+ ratio has been shown to
have a signiﬁcant effect on the potency of isoniazid, an ENR inhib-
itor inMycobacterium tuberculosis.8 There are very few examples of
inhibitors which have been designed against the NADH form of
ENR. However, a benzimidazole family of inhibitors designed as
such has modest activity against Francisella tularensis (F. tularensis)
displaying an IC50 value of 300 nM.9,10 The co-crystal structure of a
benzimidazole/NADH/ENR complex shows the inhibitor makes no
p-stacking interactions with the bound cofactor, a feature common
to triclosan and its derivatives, but instead makes a hydrogen bond
to the conserved catalytic Tyr and NADH cofactor.10 The potency of
the benzimidazole family has been shown for F. tularensis, Esche-
richia coli, Bacillus anthracis, Yersinia pestis, Staphylococcus aureus
and MRSA, but to date no antiparasitic testing has been carried
out.9
Despite its eukaryotic nature, Toxoplasma gondii (T. gondii) uses
a typical FAS II pathway making it susceptible to inhibitors of
ENR.11 This pathway is located in the apicoplast organelle and
Table 1
Data collection and reﬁnement statistics
TgENR apo
Data collection statistics
Space group C121
Wavelength used (Å) 0.97949
Resolution range (Å) 30.0–2.0 (2.03–2.0)
Unique reﬂections 129,052 (6302)
Multiplicity 3.6 (3.7)
Completeness of data (%) 99.7 (99.6)
Mean I/r (I) 6.5 (2.8)
Multiplicity 3.6 (3.7)
Rmerge (%) 0.13 (0.5)
Reﬁnement Statistics
Resolution limits (Å) 30.0–2.0
Rcryst (%) 16.9
Rfree (%) 19.9
Rmsd values
Bond length (Å) 0.015
Bond angle (deg.) 1.54
Ramachandran plota
Most favoured (%) 97.9
Additionally allowed (%) 2.1
Generously allowed (%) 0.0
Disallowed (%) 0.0
Molecules in asymm. unit 6
Protein atoms 13,302
Co-factor atoms 264
Water molecules 415
Mean B-values (Å2)
Protein Mainchain/sidechain 9/13
Co-factors 17
Water molecules 15
Data was collected at station I02 at the Diamond synchrotron to 2.0 Å. Values in
parentheses are for the highest resolution shell.
a Ramachandran values were determined in PROCHECK.30
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last such as Plasmodium (species) and Eimeria (species) possess this
pathway and are known to be susceptible to ENR targeted drugs.11–
13 Although FAS II and ENR play an important role in liver-stage
development of P. falciparum it is not essential for the survival of
blood stages where triclosan would therefore appear to have an
off-target effect.14,15
The development of a novel set of ENR/NADH inhibitors against
F. tularensis has provided a new potential therapeutic avenue for
the development of T. gondii inhibitors. Here we demonstrate the
benzimidazole family of compounds shows no inhibition of T. gon-
dii ENR (TgENR) at 1 lM. However, the same inhibitors show
promising activity with a MIC50 value of between 1 and 10 lM
against two different strains of T. gondii parasites cultured
in vitro. The ability of these compounds to curtail T. gondii growth,
but not affect ENR activity, suggests that they have an off-target ef-
fect. Consistent with this idea, a structurally similar compound
Chlormidazole is active against fungi which have a type I and not
a type II fatty acid biosynthesis pathway and lack an ENR homo-
logue, indicating an alternative primary target in fungi, most likely
14 alpha methylase. Although T. gondii lacks this enzyme, data
mining of the PubChem compound library has shown a number
of similar scaffolds with different targets which may explain some
of the off-target affects evident against T. gondii.
Johnson et al. reported that the 3,4-dichloro substituted benz-
imidazole 1 was potent against F. tularensis ENR (FtENR) com-
plexed with NADH.9 Hit compound 1 and two derivatives 2 and 3
were synthesized from commercially available 5,6-dimethylbenz-
imidazole and substituted benzyl bromides using NaH and KI in
DMF, in moderate to good yields (Scheme 1). HPLC determined
purity to be >95% for each compound.
The ﬁbroblast host cell toxicity assays, inhibition assays and
parasite replication assays were performed as previously de-
scribed.16–20
Cell toxicity assays were carried out in PC3-Luc cells. Conﬂuent
cells were incubated with compounds 1–3 at 10 nM, 100 nM, 1 lM
and 10 lM concentration in phenol red free DMEM (supplemented
with 10% FCS, 1% L-glutamine and 1% penicillin streptomycin). At
48 and 96 h the cells were supplemented with 150 lg/ml D-lucif-
erin potassium salt and imaged for 1 min in an IVIS Spectrum
(Perkinelmer, USA).
To investigate if the benzimidazole compounds had a similar
binding mode in TgENR as described for FtENR, co-crystallisation
experiments were conducted.10 In the ﬁrst instance crystals were
grown in the presence of 1.6 mM inhibitor, which was more than
sufﬁcient for the FtENR/NADH/Benzimidazole crystal structure.
However, this was insufﬁcient to produce a TgENR/NADH/Benz-
imidazole crystal complex. Instead, 3.2 mM of inhibitor was used
and crystals were grown in the Morpheus crystal screen from
Molecular Dimensions. Several different crystallisation conditions
yielded diffracting crystals from which data was collected to iden-
tify any bound inhibitor. The highest diffracting crystals grew in
condition G6 (0.1 M Na-Formate, NH4-Acetate, Na3-Citrate, NaK-
Tartrate, Na-Oxamate, 1 M Sodium HEPES, MOPS pH7.5, 30% v/v
P500MME_P20K). The crystals were ﬂash frozen and data were col-
lected on beamline I02 at the Diamond SRS. Full data collection and
processing statistics are found in Table 1. The coordinates haveScheme 1. Reagents and conditions: (a) NaH, Kbeen deposited within the protein data bank, accession number
4O1M.
Iterative cycles of model building and reﬁnement were carried
out to 2.0 Å resolution in COOT and REFMAC5 with PDB_REDO
optimizing the reﬁnement procedure, with resulting Rfact and Rfree
values of 0.17 and 0.20, respectively.21–23 The resulting, reﬁned
map showed clear and continuous electron density for the bound
NADH cofactor. However, there was only a small region of strong
positive Fobs–Fcalc density within the proposed binding site
(Fig. 1A). Moreover, the position of this density is not consistent
with the proposed binding site for the benzimide inhibitor
(Fig. 1B). The inhibitor could not be reﬁned either in a similar posi-
tion to that seen in FtENR or in an alternative conformation. The
features seen within the Fobs–Fcalc map within the ENR binding site
are consistent with the density associated with water and bound
crystallization additives (Fig. 1C). Despite data for several crystalli-
zation conditions being collected and processed no evidence for
benzimidazole binding could be seen, with all structures showing
features consistent with those seen in Figure 1.
Since the inability to co-crystalise TgENR with the benzimid-
azole inhibitors is not in of itself evidence that the family are poor
inhibitors, enzyme and cellular assays were used to investigate
their potency. The enzyme assays showed no inhibitory activityI, DMF, 0 C warming to rt, 16 h, 40–60%.
Figure 1. (A) Reﬁned TgENR/NADH crystal structure with the 2Fobs–Fcalc density map (blue) and 1Fobs–1Fcalc density map (green) contoured at 1.6r and 4.0r, respectively. (B)
The same view as in (A) but with the FtENR/NADH/benzimide complex superimposed in red to show the predicted position of the benzimide inhibitor. (C) Representative
density of the reﬁned TgENR/NADH structure with waters and glycerol modeled into the inhibitor binding site with the map contoured at 1.5r. For A–C, nitrogen, oxygen,
chlorine, phosphorous and carbon are colored blue, red, green, orange and yellow (TgENR)/red (FtENR), respectively. (D) Overlay of FtENR (blue sidechains) and TgENR (green
sidechains) inhibitor binding sites with bound inhibitor (yellow), NADH cofactor (green) shown in stick format. The position of the critical Tyr residue which forms a
hydrogen bond to the bound inhibitor is shown along with those residues which are signiﬁcant different between species.
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the benzimidazole compounds are very poor inhibitors of TgENR.
This discrepancy between binding of benzimidazole to TgENR
and FtENR was investigated by comparing the two binding sites.
A number of sequence changes are observed including signiﬁcant
changes in the loop region Ser242–Asp249 (TgENR numbering). A
further change which may affect binding is the substitution of
Met/Ala at the base of the binding pocket (Fig. 1D). The Methionine
residue in FtENR makes packing interactions with the bound inhib-
itor and appears to be important for stabilising the inhibitor
(Fig. 1D). The replacement with Ala in TgENR reduces the ability
of this residue to co-ordinate benzimidazole binding. This is an
important aspect of binding, as unlike with other ENR inhibitors
the benzimidazole compound is not coordinated by forming stack-
ing interactions with the bound co-factor.10 A further change is the
presence of Phe242 (TgENR numbering) which creates steric hin-
drance within the binding site, however we have previously shown
that this residue is capable of ﬂipping out of the binding site, to re-
move the steric hindrance.24 These subtle changes will likely fur-
ther reduce the potency of the benzimidazole family of inhibitors
which have been shown to have only modest activity >100,000–
300 nm against FtENR.10 In the absence of a crystal structure we
conducted docking simulations using AutoDock 4.2 of compound
1 to see if it could bind in a mode similar to that observed in
FtENR.25 The predicted binding mode of 1 within TgENR was sim-
ilar to that of FtENR with no signiﬁcant steric clashes when Phe242
is ﬂipped out of the active site. However, it is clear from the en-
zyme assay data that this is not a potent interaction with 1 lM
and 3.2 mM being insufﬁcient for inhibition and co-crystallisation,
respectively.
In conjunction with TgENR enzyme assays, parasite replication
assays were also conducted using the RH strain (type 1) and Prustrain (type 2) T. gondii stably transfected with the yellow ﬂuores-
cence gene (RH-YFP). This allows for parasite viability to be di-
rectly recorded from the relative ﬂuorescence intensity. The
ﬂuorescence intensities were measured after 72 h using a Synergy
H4 Hybrid Multi-Mode Microplate Reader with excitation/emis-
sion wavelength at 510/540 nm. Compounds 1, 2 and 3were effec-
tive against type 1 parasites with MIC50 values of 2.5 lM, 4 lM and
>10 lM, respectively (Fig. 2A). Type 2 T. gondii were also inhibited
with compounds 1 and 3 at 10 lM ((p < 0.005) (Fig. 2B)). The dif-
ference in activity of compound 2 maybe due to subtle differences
in the two types of strains used. This activity is far in excess of
what was expected based on the effects of the same compounds
on TgENR enzyme, suggesting that they have an additional off-tar-
get effect against T. gondii.
The promising parasite replication assay data shows that these
compounds may be a promising lead for novel T. gondii inhibitors.
To investigate their potential further, compounds 1, 2 and 3 were
tested for cellular toxicity on both ﬁbroblast and prostate cancer
cells (Fig. 2C and D). Importantly, none of the compounds showed
signiﬁcant toxicity, in either of the two different assays even at a
concentration of 10 lM against mammalian cells (Fig. 2C and D).
The low toxicity paired with the good MIC50 values make this fam-
ily of inhibitors a promising avenue for inhibitor design, however
the poor IC50 values makes TgENR an unlikely target. To further de-
velop the benzamidazole family we looked for possible targets
other than ENR in the PubChem database.
The PubChem search showed that similar small compound scaf-
folds have been developed which target Sterol 14 alpha-demethyl-
ase, Galanin receptor 3, Pteridine Reductase 1, transient receptor
potential cation channel C4 (TRPC4) and aldosterone synthase (Ta-
ble 2). The crystal structure for the Trypanosoma brucei Pteridine
Reductase (3GN2) shows that the additional amine group of the
Figure 2. Efﬁcacy and toxicity of compound 1–3 against T. gondii. (A) Growth of RH-YFP in human Foreskin ﬁbroblasts (HFF) measured as ﬂuorescence intensity. HFF were
infected with differing numbers of RH-YFP tachyzoites as indicated, with uninfected control HFF also shown. HFF infected with 3200 RH-YFP tachyzoites treated with
pyrimethamine/sulfadiazine (p/s) or 0.1% DMSO are additional positive and negative controls, respectively (left panel). The effect of compound 1–3 against Toxoplasma
tachyzoites was determined by measurement of RH-YFP ﬂuorescence as shown in the right hand panel. HFF were infected with 3200 RH-YFP and treated with compounds 1–
3 at the concentration indicated. Toxicity was measured using WST stain. (B) The effect of compounds 1–3 on Toxoplasma growth was determined by infecting conﬂuent
ﬁbroblasts with YFP expressing Pru strain T. gondii tachyzoites and measuring YFP ﬂorescence at 72 h. Compounds 1 and 3 effectively reduced parasite growth however at
10 lM (p < 0.005). (C) Compounds 1–3were incubated with conﬂuent luciferase expressing PC3-Luc cells to determine their toxicity against prostate cancer cells. 1% Triton X
was included as a positive control for cytotoxicity. After 96 h luciferin (150 lg/ml) was added and cytotoxicity was determined by a reduction in bioluminescent activity from
the cells. Neither compounds 1–3, nor the vehicle control resulted in a reduction of bioluminescent activity from the PC3-Luc cells. (D) The viability of host HFF cells was
assessed by WST-1 staining after 72 h of incubation of indicated compounds at 10 lM concentration. Effect of various concentrations of DMSO present in the HFF culture
medium served as a standard toxicity curve.
914 C. Wilkinson et al. / Bioorg. Med. Chem. Lett. 24 (2014) 911–916
Table 2
Activity data for the benzimidazole based scaffold inhibitors
Notebook
ID
Structure IC50 Target Organism T. gondii
MIC50
1
300 nM
>1000 nM
Enoyl-ACP Reductase
Francisella tularensis
T. gondii
3 lM
2 >1000 nM Enoyl-ACP Reductase T. gondii 4 lM
3 >1000 nM Enoyl-ACP Reductase T. gondii >10 lM
4 400a nM Pteridine Reductase 1 Trypanosoma brucei ND
5
140 nM Galanin Receptor 3 Homo Sapiens ND
668b nM Transient receptor potential cation channel C4
(TRPC4)
Homo Sapiens ND
6
ND Sterol 14a-demethylase
Fungi, Mycobacteria, Leishmania &
Trypanosoma
ND
200 nM Galanin Receptor 3 Homo Sapiens ND
7
635 nM Steroid 11-beta-hydroxylase Homo Sapiens ND
107 nM Aldosterone synthase Homo Sapiens ND
8
188 nM Steroid 11-beta-hydroxylase Homo Sapiens ND
632 nM Aldosterone synthase Homo Sapiens ND
a Value for Kiapp not IC50.
b Value for EC50 not IC50.
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bonds with Asp161 which is absent in the benzamidizole com-
pound.26 This would make it an unlikely target within Toxoplasma.
The Galanin receptor and TRPC4 have been shown to be targets of
similar compounds 5 and 6 (Table 1). However, these two proteins
are not present within Toxoplasma, making them unlikely targets. A
further target is sterol 14 alpha-demethylase, which is inhibited by
the antifungal drug Chlormidazole (6) (Table 2). Sterol 14 alpha-
demethylase is found in a range of fungi and bacteria such asMyco-
bacteria species as well as the Leishmania and Trypanosoma para-
sites. However, it is absent from apicomplexan parasites with
BLAST searches revealing only poor matches to putative cyto-
chrome P450 enzymes in T. gondii. Moreover, T. gondii, as well as
other apicomplexan parasites lack a cholesterol biosynthesis path-
way, instead relying on scavenging mechanisms.27 Further studies
have found that different sterol 14 alpha-demthylase targeting
drugs were more effective against a different cytochrome P450
CYP121 in Mycobacteria.28 An additional sterol 14 alpha-demthy-
lase inhibitor itraconazole is effective against T. gondii, however,
an additional off target has not been found and it has been hypoth-
esized that there may be several general non-speciﬁc targets in T.
gondii which account for the cellular activity.29 A similar scaffold
has been shown to display activity against steroid 11-beta-hydrox-
ylase and aldosterone synthase (7, 8). Taken together this would
suggest that despite the benzimidazole inhibitor family offering
potential as a novel inhibitor against F. tularensis ENR it has a likely
off target effect which accounts for the good MIC50 value estab-
lished against the parasite in vitro but poor IC50 value observed
against Toxoplasma ENR.
Further studies will be required to determine the exact target
of the benzimidazole family of inhibitors and establish a clear
structure-activity relationship (SAR). However, they present thepotential for novel T. gondii inhibitors given their good anti par-
asitic activity and low toxicity against both prostate and HFF
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